Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tandem Diabetes Care (TNDM) Gross Margin (2016 - 2026)

Tandem Diabetes Care filings provide 13 years of Gross Margin readings, the most recent being 57.67% for Q4 2025.

  • On a quarterly basis, Gross Margin rose 196.0% to 57.67% in Q4 2025 year-over-year; TTM through Dec 2025 was 53.81%, a 174.0% increase, with the full-year FY2025 number at 53.81%, up 174.0% from a year prior.
  • Gross Margin hit 57.67% in Q4 2025 for Tandem Diabetes Care, up from 53.88% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 57.67% in Q4 2025 to a low of 47.41% in Q4 2023.
  • Median Gross Margin over the past 5 years was 51.86% (2022), compared with a mean of 51.89%.
  • Biggest five-year swings in Gross Margin: tumbled -498bps in 2023 and later skyrocketed 830bps in 2024.
  • Tandem Diabetes Care's Gross Margin stood at 54.16% in 2021, then dropped by -3bps to 52.39% in 2022, then decreased by -10bps to 47.41% in 2023, then increased by 18bps to 55.71% in 2024, then rose by 4bps to 57.67% in 2025.
  • The last three reported values for Gross Margin were 57.67% (Q4 2025), 53.88% (Q3 2025), and 52.29% (Q2 2025) per Business Quant data.